Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Notification Letter and Reply Form to Non registered Shareholders[...]
04/20/2022 | Press release | Distributed by Public on 04/20/2022 01:38
Please select the service you want to use:
Smartlinks | Izumi Co. Ltd. | Finance | Stock Markets | Security Markets | Stock Markets | Security Markets | Company News | Top Company News | Business Announcement | Financial Services | Real Estate | Retail | Public Companies | Retail Property Development and Management Companies | OTC Markets | Tokyo Stock Exchange (TSE) | Chi-X Japan | SBI Japannext
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact